These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 17655519)
21. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. Fudio S; Carcas A; Piñana E; Ortega R J Clin Pharm Ther; 2006 Aug; 31(4):393-6. PubMed ID: 16882111 [TBL] [Abstract][Full Text] [Related]
22. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558 [TBL] [Abstract][Full Text] [Related]
23. Ertapenem-associated seizures in a patient without prior CNS disorder or severe renal dysfunction. Soštaric N; Beovic B; Maticic M Int J Clin Pharmacol Ther; 2014 Mar; 52(3):255-8. PubMed ID: 24472405 [TBL] [Abstract][Full Text] [Related]
31. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. Haroutiunian S; Ratz Y; Rabinovich B; Adam M; Hoffman A J Clin Pharmacol; 2009 Nov; 49(11):1363-9. PubMed ID: 19773524 [TBL] [Abstract][Full Text] [Related]
32. Divalproex sodium vs. valproic acid: drug utilization patterns, persistence rates and predictors of hospitalization among VA patients diagnosed with bipolar disorder. Iqbal SU; Cunningham F; Lee A; Wang S; Hamed A; Miller DR; Ren X; Kazis L J Clin Pharm Ther; 2007 Dec; 32(6):625-32. PubMed ID: 18021341 [TBL] [Abstract][Full Text] [Related]
33. An experimental design for finding of minimum dosage of carbamazepine and valproate in preventing of seizure attacks. Samaei A; Nobahar M; Vafaei AA Pak J Pharm Sci; 2009 Apr; 22(2):180-3. PubMed ID: 19339229 [TBL] [Abstract][Full Text] [Related]
34. A critical interaction between ertapenem and valproic acid. Molnar GP; Stephens KJ; George LV; Stewart JT J Clin Psychopharmacol; 2015 Jun; 35(3):348-50. PubMed ID: 25871574 [No Abstract] [Full Text] [Related]
36. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385 [TBL] [Abstract][Full Text] [Related]
37. Pathological case of the month: sudden death in a child as a result of pancreatitis during valproic acid therapy. Mileusnic D; Donoghue ER; Lifschultz BD Pediatr Pathol Mol Med; 2002; 21(5):477-84. PubMed ID: 12396903 [TBL] [Abstract][Full Text] [Related]
38. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Fica AE; Abusada NJ Scand J Infect Dis; 2008; 40(11-12):983-5. PubMed ID: 18759157 [TBL] [Abstract][Full Text] [Related]
39. Rapid oral loading of extended release divalproex in patients with acute mania. Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770 [TBL] [Abstract][Full Text] [Related]
40. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities? Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]